Lasso catheter guided ablation for paroxysmal atrial fibrillation: the first experience in Thailand.

The authors used the 10-pole pulmonary vein sized loop-shaped, lasso, catheter via a transatrial septal long sheath in 10 patients who had symptomatic refractory paroxysmal atrial fibrillation (PAF) in order to map and guide for catheter ablation. The radiofrequency current was delivered at the junction between atrial tissue and the pulmonary vein which was the earliest endocardial activation time of the premature atrial contraction (PAC) initiating the PAF and at the pulmonary vein potential during sinus rhythm. Twenty two foci of PAC, 10 and 7, 4 and 1 from left and right superior and left and right inferior pulmonary veins, respectively, and 5 pulmonary vein potentials, 2 and 3 from left and right superior pulmonary veins, respectively, were ablated. After AF ablation, classical atrial flutter (AFl) could be induced in 9 patients. Isthmus line of block for AFl was performed in all patients. Two patients had atrial tachycardia at the high right atrium and also successfully ablated. The mean fluoroscopic and procedure times were 87 and 300 minutes, respectively. One patient had deep vein thrombosis which resolved after anticoagulant therapy. One patient had recurrent PAF which was successfully reablated but he still had very mild symptoms. During the mean follow-up period of 5.8 months, 9 patients remained free of symptoms. Conclusion: Lasso catheter is an effective tool for mapping and guiding of ablation for PAF. However, more experience and long-term follow-up are required.

Clinical experience of sirolimus-eluting stents in patients with coronary artery disease at Bangkok Heart Institute.

Drug eluting stents represent one of the fastest growing fields in interventional cardiology today. From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson & Johnson) appear to demonstrate a remarkable efficacy and safety in preventing restenosis. From the present study, the authors reported clinical experience of SES in 40 consecutive patients with coronary artery disease (CAD) between 25th June and 11th October, 2002. The mean age was 59 +/- 12.16 years (mean +/- SD) and 80 per cent of the patients were male. The majority of the patients had chronic stable angina and most percutaneous coronary interventions were performed by elective procedure (85%). Thirty-five per cent of the patients had single vessel disease and 42.5 per cent of the patients had double vessel disease. The authors successfully implanted 52 (69.3%) SES in 75 target lesions revascularization. Twenty-four (60%) of the patients had more than 1 vessel intervention. Twenty-seven (67.5%) of the patients had complete revascularization by percutaneous coronary intervention (PCI) and only 16 of 27 patients (59.3%) who had complete revascularization with SES. The SES were usually implanted at middle part of the left anterior descending artery (MLAD) (11 lesions), proximal part of the left anterior descending artery (PLAD) (8 lesions), middle part of the right coronary artery (MRCA) (8 lesions) and middle part of the left circumflex artery (MLCX) (6 lesions). The authors had to cover plaque entirely with SES, so SES implantation usually took longer than the bare stent (BS). The authors followed the initial clinical outcome of the patients within 1 month after discharge. Few adverse clinical events were found during 1 month follow-up because SES have a very low rate of restenosis in the short-term so, we have to follow-up the patients over a longer period and will report the clinical outcome in the next study.